Abacavir sulphate (CAS 136777-48-5)
Alternate Names:
ABC; Abacavir Hemisulfate; Ziagen
Application:
Abacavir sulphate is a nucleoside reverse transcriptase inhibitor (NRTI)
CAS Number:
136777-48-5
Molecular Weight:
670.74
Molecular Formula:
C28H38N12O6S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Abacavir sulphate has properties as a nucleoside analogue, particularly in the study of viral replication mechanisms. Abacavir sulphate is utilized to understand the biochemical pathways involved in the inhibition of viral DNA synthesis, which is for the development of strategies to manage viral infections in various environmental and experimental applications. The stability and solubility of Abacavir sulphate under different conditions, which aids in improving handling and storage techniques in laboratory applications. Abacavir sulphate is involved in studies aimed at understanding its interaction with other biological molecules, which can inform the design of combination studies.
Abacavir sulphate (CAS 136777-48-5) References
- Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. | Mallal, S., et al. 2002. Lancet. 359: 727-32. PMID: 11888582
- Nevirapine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. | Laurito, TL., et al. 2002. J Mass Spectrom. 37: 434-41. PMID: 11948850
- Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. | Rauch, A., et al. 2006. Clin Infect Dis. 43: 99-102. PMID: 16758424
- Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. | Zucman, D., et al. 2007. J Acquir Immune Defic Syndr. 45: 1-3. PMID: 17356469
- HLA-B*5701 screening for hypersensitivity to abacavir. | Mallal, S., et al. 2008. N Engl J Med. 358: 568-79. PMID: 18256392
- Cariogenic and erosive potential of the medication used by HIV-infected children: pH and sugar concentration. | Pomarico, L., et al. 2008. Community Dent Health. 25: 170-2. PMID: 18839724
- Development and validation of a selective and rapid LC-MS-MS method for the quantification of abacavir in human plasma. | Yadav, M., et al. 2010. J Chromatogr Sci. 48: 654-62. PMID: 20819295
- Separation and characterization of forced degradation products of abacavir sulphate by LC-MS/MS. | Rao, RN., et al. 2011. J Pharm Biomed Anal. 54: 279-85. PMID: 20869185
- Detection of abacavir hypersensitivity by ELISpot method. | Esser, S., et al. 2012. Inflamm Allergy Drug Targets. 11: 227-34. PMID: 22338581
- A novel vaginal drug delivery system: anti-HIV bioadhesive film containing abacavir. | Ghosal, K., et al. 2014. J Mater Sci Mater Med. 25: 1679-89. PMID: 24699799
- Development of albumin-based nanoparticles for the delivery of abacavir. | Wilson, B., et al. 2015. Int J Biol Macromol. 81: 763-7. PMID: 26365020
- Antiviral Screening of Multiple Compounds against Ebola Virus. | Dowall, SD., et al. 2016. Viruses. 8: PMID: 27801778
- Stability behaviour of antiretroviral drugs and their combinations. 9: Identification of incompatible excipients. | Kurmi, M., et al. 2019. J Pharm Biomed Anal. 166: 174-182. PMID: 30654205
- HIV Antivirals Affect Endothelial Activation and Endothelial-Platelet Crosstalk. | Khawaja, AA., et al. 2020. Circ Res. 127: 1365-1380. PMID: 32998637
Inhibitor of:
HIV-1 RT.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Abacavir sulphate, 10 mg | sc-483070 | 10 mg | $124.00 | |||
Abacavir sulphate, 50 mg | sc-483070A | 50 mg | $238.00 |